BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 27835590)

  • 1. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
    Li Q; Hou J; Hu Z; Gu B; Shi Y
    Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis.
    Xie ZC; Li TT; Gan BL; Gao X; Gao L; Chen G; Hu XH
    Pathol Res Pract; 2018 May; 214(5):644-654. PubMed ID: 29650443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
    Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
    World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation.
    Luo J; Shi K; Yin SY; Tang RX; Chen WJ; Huang LZ; Gan TQ; Cai ZW; Chen G
    World J Surg Oncol; 2018 Apr; 16(1):76. PubMed ID: 29636077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
    Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
    Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
    Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
    Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma.
    Chen WJ; Gan TQ; Qin H; Huang SN; Yang LH; Fang YY; Li ZY; Pan LJ; Chen G
    Pathol Res Pract; 2017 Apr; 213(4):364-372. PubMed ID: 28214218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation.
    Gao L; Guo YN; Zeng JH; Ma FC; Luo J; Zhu HW; Xia S; Wei KL; Chen G
    Int J Oncol; 2019 May; 54(5):1651-1664. PubMed ID: 30896821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of crucial regulatory relationships between long non-coding RNAs and protein-coding genes in lung squamous cell carcinoma.
    Wu X; Ruan L; Yang Y; Mei Q
    Mol Cell Probes; 2016 Jun; 30(3):146-52. PubMed ID: 26928440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.
    Zhang R; Zhang TT; Zhai GQ; Guo XY; Qin Y; Gan TQ; Zhang Y; Chen G; Mo WJ; Feng ZB
    World J Surg Oncol; 2018 Jun; 16(1):109. PubMed ID: 29914539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.